CAS No. |
13647-35-3 |
|---|---|
中文名称 |
(1aR,4aR,4bS,6aS,7S,9aS,9bS,11aS)-2,7-二羟基-4a,6a-二甲基-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-十四氢环戊并[7,8]菲并[1,10a-b]环氧乙烯-3-甲腈 |
英文名称 |
(1aR,4aR,4bS,6aS,7S,9aS,9bS,11aS)-2,7-dihydroxy-4a,6a-dimethyl-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-tetradecahydrocyclopenta[7,8]phenanthro[1,10a-b]oxirene-3-carbonitrile |
别名 |
Trilostane | 13647-35-3 | Modrenal | Vetoryl | Desopan | Modrastane | Trilostano | Trilostanum | Win-24540 | WIN 24,540 | CHEBI:32260 | UNII-L0FPV48Q5R | L0FPV48Q5R | Win 24540 | DTXSID9023706 | EINECS 237-133-0 | Trilostanum [INN-Latin] | WIN 24450 | Trilostano [INN-Spanish] | NSC-758904 | And |
标准英文名 |
(1aR,4aR,4bS,6aS,7S,9aS,9bS,11aS)-2,7-dihydroxy-4a,6a-dimethyl-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-tetradecahydrocyclopenta[7,8]phenanthro[1,10a-b]oxirene-3-carbonitrile |
MDL No. |
MFCD00199295 |
分子式 |
C20H27NO3 |
分子量 |
329.20 |
精确分子量 |
329.20 |
SMILES |
C[C@@]12[C@@]3(CC[C@]4([H])[C@]2([H])CC[C@]5([C@@]4([H])CC[C@@H]5O)C)[C@](C(O)=C(C1)C#N)([H])O3 |
标准SMILES |
C[C@]12CC(C#N)=C(O)[C@H]3O[C@@]13CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@H]2O |
用途 |
Trilostane is used for the treatment of Cushing's syndrome (hypercortisolism) and primary hyperaldosteronism by inhibiting 3β-hydroxysteroid dehydrogenase, thereby reducing the synthesis of cortisol and aldosterone; it is also used in veterinary medicine to alleviate symptoms of Cushing's syndrome in dogs; additionally, it is employed in the treatment of advanced, hormone receptor-positive breast cancer in postmenopausal women, where it acts as a dual modulator of estrogen receptors—functioning as an α-estrogen receptor antagonist and a β-estrogen receptor agonist—and also inhibits cell proliferation via the AP-1 site on DNA. |
InChIKey |
KVJXBPDAXMEYOA-CXANFOAXSA-N |
|
|
评论 |
|---|